Lutetium Treatment
Treatment with LUTETIUM-177 (Lu-177) Marked Compounds
Treatment towards metastatic prostate cancer and neuroendocrine tumors are provided with Lu-177 marked compounds.While Lu-177 marked DOTA peptides are used in neuroendocrine tumors, Lu-177 marked PSMA are used in prostate cancer. Imaging performed with Ga-68 marked compounds is an advisor while deciding on suitability for treatment.
Thanks to these smart compounds that Lu-177 is attached to, it is carried to tumor cells following intravenous injection and these cells are intended to be radiated.
Treatment plan is generally made in 4-6 cycles with 6-8 week intervals. Hospitalization time is approximately 1 day.
The aim of the treatment is to reduce the tumor, stop its spread and reduce the side effects caused by the disease. It increases the length of life in patient groups who cannot be treated surgically in neuroendocrine tumors and increase their quality of life.
There are strong evidences regarding to the contribution of Lu-177-PSMA treatment in terms of length of life and quality of life in those with advanced stage prostate cancer who could not be treated by other treatments.